Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 1
Submit an article Journal homepage
142
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust

Richard Hintona London North West University Healthcare NHS Trust, Harrow, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2683-4615
ORCID Icon,
George Nesrb Catherine Lewis Centre Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom of Great Britain and Northern IrelandORCID Iconhttps://orcid.org/0000-0001-7147-843X
ORCID Icon,
Catherine Garnetta London North West University Healthcare NHS Trust, Harrow, UKORCID Iconhttps://orcid.org/0000-0002-9386-0485
ORCID Icon,
David Foldesa London North West University Healthcare NHS Trust, Harrow, UK
,
Joel James Robert McCayc Department of Haematology,Hammersmith Hospitals NHS Trust, London, United Kingdom of Great Britain and Northern IrelandORCID Iconhttps://orcid.org/0000-0003-2486-3655
ORCID Icon,
Rachael Medlanda London North West University Healthcare NHS Trust, Harrow, UK
,
Huseini Kagdid Department of Haematology, London North West Healthcare NHS Trust, Harrow, United Kingdom of Great Britain and Northern Ireland
,
Vaitsa Katsomitroud Department of Haematology, London North West Healthcare NHS Trust, Harrow, United Kingdom of Great Britain and Northern Ireland
,
Hau Wui Sima London North West University Healthcare NHS Trust, Harrow, UK
,
Sameer Gandhia London North West University Healthcare NHS Trust, Harrow, UK
,
Agapi Parcharidoua London North West University Healthcare NHS Trust, Harrow, UK
&
Siamak Aramid Department of Haematology, London North West Healthcare NHS Trust, Harrow, United Kingdom of Great Britain and Northern Ireland
 show all
Pages 227-230 | Received 21 May 2021, Accepted 21 Aug 2021, Published online: 02 Sep 2021

References

  • Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892.
  • Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e745.
  • García-Suárez J, de la Cruz J, Cedillo Á, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13(1):133.
  • Garnett C, Foldes D, Bailey C, et al. Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom. Leuk Lymphoma. 2021;62(2):469–472.
  • Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg3055.
  • Monin, L, Laing, A.G, Muñoz-Ruiz, M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. The Lancet Oncology, 2021;22(6):765–778.
  • Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384(8):693–704.
  • Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826.
  • Abani O, Abbas A, Abbas F, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2021;397(10285):1637–1645.
  • Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859–1865.
  • Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173.
  • Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science. 2021;371(6530):741–745.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.